These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 29967001)
1. Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma. Fridley BL; Dai J; Raghavan R; Li Q; Winham SJ; Hou X; Weroha SJ; Wang C; Kalli KR; Cunningham JM; Lawrenson K; Gayther SA; Goode EL Cancer Epidemiol Biomarkers Prev; 2018 Sep; 27(9):1101-1109. PubMed ID: 29967001 [No Abstract] [Full Text] [Related]
2. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714 [TBL] [Abstract][Full Text] [Related]
5. Low expression of miR-449 in gynecologic clear cell carcinoma. Jang SG; Yoo CW; Park SY; Kang S; Kim HK Int J Gynecol Cancer; 2014 Nov; 24(9):1558-63. PubMed ID: 25238166 [TBL] [Abstract][Full Text] [Related]
6. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725 [TBL] [Abstract][Full Text] [Related]
7. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620 [TBL] [Abstract][Full Text] [Related]
8. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232 [TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological study of SET subtype of ovarian high-grade serous carcinoma]. Sun YW; Shen DH; Cui SS; He HJ; Zhang XL; Wang W; Liu CR Zhonghua Fu Chan Ke Za Zhi; 2019 Sep; 54(9):595-600. PubMed ID: 31550775 [No Abstract] [Full Text] [Related]
10. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118 [TBL] [Abstract][Full Text] [Related]
11. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma]. Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967 [No Abstract] [Full Text] [Related]
12. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. Peres LC; Cushing-Haugen KL; Köbel M; Harris HR; Berchuck A; Rossing MA; Schildkraut JM; Doherty JA J Natl Cancer Inst; 2019 Jan; 111(1):60-68. PubMed ID: 29718305 [TBL] [Abstract][Full Text] [Related]
13. Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. Mackenzie R; Talhouk A; Eshragh S; Lau S; Cheung D; Chow C; Le N; Cook LS; Wilkinson N; McDermott J; Singh N; Kommoss F; Pfisterer J; Huntsman DG; Köbel M; Kommoss S; Gilks CB; Anglesio MS Am J Surg Pathol; 2015 Nov; 39(11):1548-57. PubMed ID: 26099008 [TBL] [Abstract][Full Text] [Related]
14. Ovarian Carcinoma: A Single-Centre Eight-Year Case-Series Study with Survival Analysis. Subtirelu GD; Steriu A; Bratucu E Chirurgia (Bucur); 2024 Aug; 119(4):373-384. PubMed ID: 39250607 [No Abstract] [Full Text] [Related]
15. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889 [TBL] [Abstract][Full Text] [Related]
16. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin. Morency E; Leitao MM; Soslow RA Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225 [TBL] [Abstract][Full Text] [Related]
17. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary. Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452 [TBL] [Abstract][Full Text] [Related]
18. Histotype-specific copy-number alterations in ovarian cancer. Huang RY; Chen GB; Matsumura N; Lai HC; Mori S; Li J; Wong MK; Konishi I; Thiery JP; Goh L BMC Med Genomics; 2012 Oct; 5():47. PubMed ID: 23078675 [TBL] [Abstract][Full Text] [Related]
19. Apparent diffusion coefficient (ADC) values of serous, endometrioid, and clear cell carcinoma of the ovary: pathological correlation. Ono T; Kishimoto K; Tajima S; Maeda I; Takagi M; Suzuki N; Mimura H Acta Radiol; 2020 Jul; 61(7):992-1000. PubMed ID: 31698924 [TBL] [Abstract][Full Text] [Related]
20. Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas. Agostini A; Brunetti M; Davidson B; Göran Tropé C; Heim S; Panagopoulos I; Micci F Int J Cancer; 2018 Sep; 143(6):1379-1387. PubMed ID: 29633253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]